Pay in 4 interest-free payments of $5.57 Learn more
Ships within 48 hours · Estimated delivery Oct 27 - Nov 1
By Sarah M
RNA-seq analysis mRNA-seq was performed by the Single-Cell Omics platform at the Novo Nordisk Foundation Center for Basic Metabolic Research
Start Your Medical Weight Loss Journey Free 15-minute discovery call with our Houston team
This fat-to-lean ratio is comparable to what has been reported for semaglutide (around 39% lean in STEP 1) and tirzepatide (around 25-33% lean in SURMOUNT-1) retatrutide does not appear to preserve muscle better or worse than the existing GLP-1-based drugs in this dataset, though the obesity-only Phase 3 population has not yet been measured
Ongoing Clinical Trials 2025 NCT05552444 A Phase II trial of selumetinib and everolimus in advanced NF1-related MPNST
US$ 29.20
US$ 21.68
US$ 29.81
US$ 21.58
